NCT02311920 2023-01-10Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or GliosarcomaNational Cancer Institute (NCI)Phase 1 Completed32 enrolled